GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adimmune Corp (TPE:4142) » Definitions » Ending Cash Position

Adimmune (TPE:4142) Ending Cash Position : NT$2,345 Mil (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Adimmune Ending Cash Position?

Adimmune's Ending Cash Position for the quarter that ended in Dec. 2024 was NT$2,345 Mil.

Adimmune's quarterly Ending Cash Position declined from Jun. 2024 (NT$2,198 Mil) to Sep. 2024 (NT$1,800 Mil) but then increased from Sep. 2024 (NT$1,800 Mil) to Dec. 2024 (NT$2,345 Mil).

Adimmune's annual Ending Cash Position declined from Dec. 2022 (NT$2,857 Mil) to Dec. 2023 (NT$2,458 Mil) and declined from Dec. 2023 (NT$2,458 Mil) to Dec. 2024 (NT$2,345 Mil).

Adimmune Ending Cash Position Historical Data

The historical data trend for Adimmune's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adimmune Ending Cash Position Chart

Adimmune Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,087.46 2,652.02 2,857.08 2,457.50 2,344.62

Adimmune Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,457.50 2,979.15 2,197.89 1,800.25 2,344.62

Adimmune Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Adimmune's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2457.501+-112.881
=2,345

Adimmune's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1800.249+544.371
=2,345

Adimmune Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Adimmune's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Adimmune Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adimmune Corp (TPE:4142) » Definitions » Ending Cash Position
Comparable Companies
ROCO:7759 TPE:6949 ROCO:4157 ROCO:6875 ROCO:6586 ROCO:4726 ROCO:4167 TPE:1760 ROCO:6976 TPE:1734 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
Tanxing Road, No. 3, Sector 1, Tanzi District, Taichung, TWN, 427003
Website
https://www.adimmune.com.tw
Adimmune Corp is a Taiwan-based company. It is engaged in the development, manufacture, and distribution of vaccines and other biological products. Its pipeline consists of products like AdimFlu-S (QIS) which is a vaccine intended for use in the prevention of influenza, and TetraFlu among others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from the USA, China, and other regions.

Adimmune Headlines

No Headlines